ANAL BASALOID CARCINOMA
Clinical trials for ANAL BASALOID CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new ANAL BASALOID CARCINOMA trials appear
Sign up with your email to follow new studies for ANAL BASALOID CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immunotherapy trial aims to stop anal Cancer's comeback
Disease control OngoingThis study is testing if adding the immunotherapy drug nivolumab after standard chemoradiation treatment can help keep high-risk anal cancer from coming back. It involves 344 adults who have completed their initial cancer treatment. Participants are randomly assigned to either re…
Matched conditions: ANAL BASALOID CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
Could less treatment be enough for early anal cancer?
Disease control OngoingThis study is testing if a lower dose of chemotherapy combined with radiation works as well as the standard, stronger dose for treating early-stage anal cancer. It aims to see if the lower dose can still control the cancer while causing fewer side effects, like bowel and sexual p…
Matched conditions: ANAL BASALOID CARCINOMA
Phase: PHASE2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC
-
Major trial aims to boost survival for advanced anal cancer
Disease control OngoingThis large, late-stage trial is testing whether adding an immunotherapy drug (nivolumab) to standard chemotherapy works better than chemotherapy alone for anal cancer that has spread. It will enroll about 205 adults whose cancer cannot be cured by surgery or radiation. The main g…
Matched conditions: ANAL BASALOID CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 11, 2026 14:53 UTC